- Starpharma has provided updates on its COVID-19 nasal protection spray, which uses antiviral dendrimer SPL7013
- Already the company has identified a manufacturer and device components, undertook pilot manufacturing, and compiled regulatory documents
- Depending on discussions with regulators, Starpharma expects to accelerate approval of a SPL7013 nasal spray
- SPL7013 works by blocking the interaction between viral surface proteins and human cell receptor proteins
- Further, Starpharma hasn’t ruled out other applications for SPL7013, such as injection, ocular (through the eye), or mist inhalation
- Starpharma is currently up a steady 9.52 per cent and shares are trading for $1.15 each
